Life Science News

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has assumed full commercial activities and is re-launching Exelon ® (rivastigmine) in Brazil following successful transfer of the marketing authorization.

On May 26, 2021, Knight completed the acquisition of the exclusive rights to manufacture, market and sell Exelon ® in Canada and Latin America as well as the exclusive license to use the intellectual property and the Exelon trademark, from Novartis within those territories.

Exelon ® is a prescription product that was first approved in 1997 and is currently registered and sold in approximately 90 countries. Exelon ® is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease. Knight had entered into a transition service agreement with Novartis until transfer of marketing authorizations, on a country-by-country basis.

"Exelon ® is an important therapeutic option for patients with Alzheimer's disease, and we look forward to engaging with the Alzheimer's community in Brazil to support patients and caregivers affected by this debilitating disease,"   said Samira Sakhia, President & Chief Executive Officer of Knight.

"Alzheimer's disease remains a growing problem worldwide and in Brazil. The number of individuals suffering from Alzheimer's and other dementias is expected to double by 2030 which underscores the need for treatments like Exelon®. We emphasize the importance of companies like Knight that take an active interest in supporting this area of such high unmet need," said Dr. Marco Túlio Gualberto Cintra, Geriatrician and Associate Professor at the department of internal medicine at Federal University of Minas Gerais (UFMG).

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com . Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law.

Investor Contact

Knight Therapeutics Inc.

Samira Sakhia
Arvind Utchanah
President & Chief Executive Officer Chief Financial Officer
T: 514.484.4483 T. +598.2626.2344
F: 514.481.4116
Email: info@knighttx.com Email: info@knighttx.com
Website: www.gud-knight.com Website: www.gud-knight.com

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

GUD:CA

SALIX PHARMACEUTICALS APPLAUDS IMPLEMENTATION OF K76.82 - A NEW ICD-10 CODE FOR HEPATIC ENCEPHALOPATHY

Centers for Medicare & Medicaid Services (CMS) Launch of New Code Coincides with Liver Awareness Month, a Time to Make Liver Health a National Health Care Priority

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) and liver diseases and disorders, announced today, their endorsement of the implementation of K76.82, an ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE), a complication of cirrhosis that affects the brain. According to recent data, hospitalized patients readmitted within 30 days with HE have a 20% 1-year mortality rate. 1

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
ALR Technologies Announces Update to Singapore Migration Merger and GluCurve Pet CGM Commercialization

ALR Technologies Announces Update to Singapore Migration Merger and GluCurve Pet CGM Commercialization

ALR Technologies Inc. ("ALRT") (OTCQB: ALRT), the diabetes management company, is pleased to announce an update with respect to its migration to Singapore. Further to its Form 8-K filed May 20, 2022, and press release issued May 20, 2022, the Registration Statement on Form F-4 filed by its affiliate, ALR Technologies SG Ltd. ("ALRT Singapore"), has been declared effective by the Securities and Exchange Commission (the "SEC"). ALRT anticipates mailing the corresponding prospectus and information statement to its stockholders on or around October 4, 2022. ALRT expects to consummate the previously announced reincorporation merger in which ALRT will become a wholly owned subsidiary of ALRT Singapore as soon as practicable following the required 20-day waiting period subsequent to mailing of the prospectus and information statement, subject to the satisfaction of customary closing conditions, including certain regulatory approvals from FINRA, the OTC Markets Group, ACRA (Singapore), and the Secretaries of State of Nevada and Delaware.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific to Source Half of its U.S. Electricity Needs from Wind Power Purchase with Enel North America

The agreement will deliver renewable energy equal to half of the company's U.S. electricity consumption

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, recently signed an eight-year virtual power purchasing agreement with Enel North America to deliver a 90-megawatt (MW) portion of the Seven Cowboy wind project in western Oklahoma. Thermo Fisher will purchase approximately 400,000 megawatt hours (MWh) of renewable electricity, equal to half of the company's current U.S. electricity needs.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
6 Small Medical Device Companies (Updated 2022)

6 Small Medical Device Companies (Updated 2022)

The medical device sector in Canada may be one of the country’s best-kept global secrets.

According to the Canadian government, the nation has a large number of medical device manufacturers working to advance product innovation. Data from 2020, the most recent period available, shows that the country brought US$7.5 billion to the medical device sector that year, which is 1.8 percent of the worldwide market.

Medical devices include items like pacemakers, artificial heart valves, diagnostic and imaging equipment, in vitro diagnostics, dialysis equipment, hip and knee implants, synthetic skin, surgical tools, orthopedics, medical imaging and infusion pumps.

Keep reading...Show less

Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations

Bausch Health Companies Inc. (NYSETSX: BHC) (the "Company") announced today the final results and expiration of its previously announced offers (the "Exchange Offers") to exchange the existing senior notes set forth in the table below (the "Existing Senior Notes") for up to an aggregate principal amount of $4.0 billion (the "Maximum New Secured Notes Amount") of New Secured Notes (as defined below) and the related solicitations of consents (the "Consent Solicitations" and, together with the Exchange Offers, the "Offers") to amend certain provisions of the indentures (the "Proposed Amendments") with respect to the respective applicable series of Existing Senior Notes. The terms and conditions of the offers and consent solicitations are described in an Exchange Offer Memorandum and Consent Solicitation Statement, dated August 30, 2022 (the "Exchange Offer Memorandum").

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company

Modern name, purpose, and visual identity mark inspiring next chapter for maker of iconic, trusted brands, including Tylenol, Neutrogena, Listerine, and Band-Aid Brand

Johnson & Johnson (the "Company") (NYSE: JNJ) today took another step forward in establishing two independent, market-leading companies with the announcement of Kenvue as the name for the planned New Consumer Health Company. The new corporate brand comes to life through a compelling purpose, and a timeless visual brand.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×